252 related articles for article (PubMed ID: 37367084)
21. Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance.
Fleischmann M; Fischer M; Schnetzke U; Fortner C; Kirkpatrick J; Heidel FH; Hochhaus A; Scholl S
Cells; 2021 Nov; 10(11):. PubMed ID: 34831215
[TBL] [Abstract][Full Text] [Related]
22. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
23. The role of FLT3 kinase as an AML therapy target.
Beffinger M; Skwarska A
Curr Pharm Des; 2012; 18(19):2758-65. PubMed ID: 22390761
[TBL] [Abstract][Full Text] [Related]
24. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
[TBL] [Abstract][Full Text] [Related]
25. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.
Yen SC; Chen LC; Huang HL; HuangFu WC; Chen YY; Eight Lin T; Lien ST; Tseng HJ; Sung TY; Hsieh JH; Huang WJ; Pan SL; Hsu KC
Bioorg Chem; 2022 Apr; 121():105675. PubMed ID: 35182882
[TBL] [Abstract][Full Text] [Related]
26. Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies.
Zhou J; Chng WJ
World J Clin Oncol; 2018 Sep; 9(5):90-97. PubMed ID: 30254964
[TBL] [Abstract][Full Text] [Related]
27. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
28. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
[TBL] [Abstract][Full Text] [Related]
29. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in
Zhang W; Ly C; Ishizawa J; Mu H; Ruvolo V; Shacham S; Daver N; Andreeff M
Haematologica; 2018 Oct; 103(10):1642-1653. PubMed ID: 29773601
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; Ballesta-López O; Barragán E; Martínez-Cuadrón D; Montesinos P
Blood Rev; 2020 Nov; 44():100675. PubMed ID: 32147087
[TBL] [Abstract][Full Text] [Related]
31. Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.
Zhong Y; Qiu RZ; Sun SL; Zhao C; Fan TY; Chen M; Li NG; Shi ZH
J Med Chem; 2020 Nov; 63(21):12403-12428. PubMed ID: 32659083
[TBL] [Abstract][Full Text] [Related]
32. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
33. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
Larrosa-Garcia M; Baer MR
Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
[TBL] [Abstract][Full Text] [Related]
34. The Effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on the Expression of Immune Checkpoint Ligands in Acute Myeloid Leukemia Cell Line.
Taghiloo S; Norozi S; Asgarian-Omran H
Iran J Allergy Asthma Immunol; 2022 Apr; 21(2):178-188. PubMed ID: 35490271
[TBL] [Abstract][Full Text] [Related]
35. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
[TBL] [Abstract][Full Text] [Related]
36. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Hauge M; Bruserud Ø; Hatfield KJ
Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
[TBL] [Abstract][Full Text] [Related]
37. FLT3-targeted treatment for acute myeloid leukemia.
Arai Y; Chi S; Minami Y; Yanada M
Int J Hematol; 2022 Sep; 116(3):351-363. PubMed ID: 35532877
[TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia.
Jiang K; Li X; Wang C; Hu X; Wang P; Tong L; Tu Y; Chen B; Jin T; Wang T; Wang H; Han Y; Gui R; Yang J; Liu T; Li J; Zhou Y
Leukemia; 2023 Mar; 37(3):539-549. PubMed ID: 36526736
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]